2,6-difluoro-3,4-dihydroxyphenylalanine and Parkinson Disease

2,6-difluoro-3,4-dihydroxyphenylalanine has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Behnke, S; Berg, D; Buchholz, HG; Dillmann, U; Fuss, G; Krick, CM; Reith, W; Schreckenberger, M; Schroeder, U	1

Other Studies

1 other study(ies) available for 2,6-difluoro-3,4-dihydroxyphenylalanine and Parkinson Disease

Article	Year
Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. NeuroImage, 2009, Oct-01, Volume: 47, Issue:4 Topics: Adult; Dihydroxyphenylalanine; Echoencephalography; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Reference Values; Substantia Nigra	2009

Article

Year

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET.

NeuroImage, 2009, Oct-01, Volume: 47, Issue:4

Topics: Adult; Dihydroxyphenylalanine; Echoencephalography; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Reference Values; Substantia Nigra

2009